Verastem Announces $150M Debt Financing To Support VS-6766, Defactinib DevelopmentBenzinga • 03/28/22
Verastem Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company ProgressBusiness Wire • 03/28/22
Verastem Oncology Provides Financial Update to Support Development of VS-6766 and Defactinib in RAS Pathway-Driven TumorsBusiness Wire • 03/28/22
Verastem Oncology Names Preeminent Oncology Researcher Channing Der, PhD, to its Scientific Advisory BoardBusiness Wire • 03/24/22
Verastem Oncology Outlines Key 2022 Strategic Priorities and Upcoming Catalysts for Advancing VS-6766 as a Backbone of Therapy for RAS Pathway-Driven CancersBusiness Wire • 01/11/22
Mirati Therapeutics and Verastem Oncology Partner to Evaluate Adagrasib in Combination with VS-6766 in KRASG12C-Mutant Non-Small Cell Lung CancerPRNewsWire • 11/22/21
Week 46 MDA Breakout Stocks - November 2021: Short-Term Picks To Give You An EdgeSeeking Alpha • 11/13/21
Verastem Oncology Reports Third Quarter 2021 Financial Results and Highlights Recent Company ProgressBusiness Wire • 11/04/21
Penny Biotech Stocks: 8 Things for Verastem Investors to Know as VSTM Stock Shoots HigherInvestorPlace • 09/20/21
Verastem Oncology and Amgen Partner to Evaluate VS-6766 in Combination with LUMAKRASTM (Sotorasib) in Patients with KRAS G12C-Mutant Non-Small Cell Lung CancerBusiness Wire • 09/20/21
Verastem Shares Are Trading Higher On Encouraging Combo Therapy Data At ESMO PresentationBenzinga • 09/20/21
Verastem Oncology Announces Updated Investigator-Sponsored Phase 1/2 FRAME Study Data of VS-6766 with Defactinib in Low-Grade Serous Ovarian Cancer Showing Encouraging Response Rates and Progression-Free Survival Presented at ESMO 2021Business Wire • 09/19/21